Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

Real World Study of PEGylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Prevention of Chemotherapy-induced Neutropenia

The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.

Studieoversikt

Status

Ukjent

Intervensjon / Behandling

Studietype

Observasjonsmessig

Registrering (Forventet)

1500

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.

Beskrivelse

Inclusion Criteria:

  1. Patients' age≥18 years old, male or female
  2. Diagnosis of non-myeloid malignant solid tumors
  3. Patients are planned to perform chemotherapy and preventive use the PEG-rhG-CSF or preventive or therapeutic use of rhG-CSF after chemotherapy
  4. Patients' mental status are well, could understand the study and willing to participate the study, sign the informed consent form
  5. The investigator believes that patients can benefit from this study

Exclusion Criteria:

  1. Patients who have been confirmed to be allergic to Jinyouli® or rhG-CSF or its excipients
  2. Pregnant or lactating women and women who plan to be pregnant during clinical observation
  3. Other patients that the doctor believe not suitable for inclusion

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
PEG-rhG-CSF group
This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Andre navn:
  • Jinyouli
rhG-CSF group
This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cost-Effectiveness
Tidsramme: through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month
Based on the results of the incidence of febrile neutropenia(FN) and the cost perFN in each group, the incremental cost-effectiveness ratio were estimated using the following formula: (CostA-CostB)/(OutcomeA-OutcomeB)
through the chemotherapy cycles of PEG-rhG-CSF or rhG-CSF treatment,an average of 3 month

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The incidence of febrile neutropenia
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
Febrile neutropenia (FN) is defined as oral temperature >38.3 ℃(under arm temperature >38.1 ℃) or continuous measurement of oral temperature >38℃(under arm temperature >37.8℃) in 2h, and absolute neutrophil count(ANC) <0.5×10^9/L, or expected to be <0.5×10^9/L
From date of randomization until the date of the study completion,an average of 3 month
The incidence of grade IV neutropenia
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
Grade IV neutropenia is defined as the absolute neutrophil count(ANC)<0.5×10^9/L
From date of randomization until the date of the study completion,an average of 3 month
The duration of grade IV neutropenia in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
Defined as days when the ANC<2.0×10^9/L occurs to the time when the ANC≥2.0×10^9/L, take the median
From date of randomization until the date of the study completion,an average of 3 month
The incidence of the chemotherapy delay
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
Chemotherapy delay is defined as the delay in starting the next planned chemotherapy for more than 3 days.
From date of randomization until the date of the study completion,an average of 3 month
The duration of the chemotherapy delay in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
The duration of the chemotherapy delay in every chemotherapy cycle
From date of randomization until the date of the study completion,an average of 3 month
The incidence of the dose reduction
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
The incidence of the reduction of planned dose of chemotherapy
From date of randomization until the date of the study completion,an average of 3 month
Relative chemotherapy dose intensity in every chemotherapy cycle
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
Relative chemotherapy dose intensity is defined as the actual chemotherapy dose the patient used divided by the planned chemotherapy dose,or the actual chemotherapy time divided by the planned chemotherapy time
From date of randomization until the date of the study completion,an average of 3 month

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events
Tidsramme: From date of randomization until the date of the study completion,an average of 3 month
All adverse events will be recorded from the time of patients signing the informed consent form up to 30 days after the last Intervention drug is applied. the adverse event that associated with the study drug will be specially recorded.
From date of randomization until the date of the study completion,an average of 3 month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Forventet)

13. februar 2019

Primær fullføring (Forventet)

1. april 2020

Studiet fullført (Forventet)

1. oktober 2020

Datoer for studieregistrering

Først innsendt

14. februar 2019

Først innsendt som oppfylte QC-kriteriene

18. februar 2019

Først lagt ut (Faktiske)

19. februar 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. februar 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. februar 2019

Sist bekreftet

1. februar 2019

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CSPC-JYL-RWS-07

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

IPD will only be shared by the investigators in this study

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere